Abiopharma

🔍 Leopold Robin (Executive)

Company: JPMORGAN CHASE & CO (JPM)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 24,895 shares of Performance Share Units (Derivative)
  Date: 2026-03-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 24,894.77 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3

Footnotes:

• F1: Each Performance Share Unit (PSU) represents a contingent right to receive one share of JPM common stock upon vesting based on the attainment of performance goals.
• F2: Represents PSUs earned (including reinvested dividend equivalents) based on the Firm's attainment of pre-established performance goals for the three-year performance period ended December 31, 2025. The PSUs are expected to vest and settle in shares of common stock on March 25, 2026, which will be reported in a later Form 4 filing. In accordance with the terms of the PSUs, the Board's Compensation & Management Development Committee has certified the Firm's absolute and relative performance against the pre-established performance goals for the performance period and has determined that the maximum amount of the previously granted PSUs has been earned.
• F3: Shares delivered, after applicable tax withholding, must be held for an additional two-year period, for a total combined vesting and holding period of five years from the date of grant, as provided under the terms of the PSU award granted on January 17, 2023.